IRLAB Therapeutics AB (OSTO:IRLAB A) Total Liabilities : kr59.92 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Total Liabilities?

IRLAB Therapeutics AB's Total Liabilities for the quarter that ended in Mar. 2024 was kr59.92 Mil.

IRLAB Therapeutics AB's quarterly Total Liabilities increased from Sep. 2023 (kr38.94 Mil) to Dec. 2023 (kr61.36 Mil) but then declined from Dec. 2023 (kr61.36 Mil) to Mar. 2024 (kr59.92 Mil).

IRLAB Therapeutics AB's annual Total Liabilities declined from Dec. 2021 (kr72.97 Mil) to Dec. 2022 (kr32.72 Mil) but then increased from Dec. 2022 (kr32.72 Mil) to Dec. 2023 (kr61.36 Mil).

IRLAB Therapeutics AB Total Liabilities Historical Data

The historical data trend for IRLAB Therapeutics AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Total Liabilities Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

26.24

22.19

72.97

32.72

61.36

IRLAB Therapeutics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															46.18	43.62	38.94	61.36	59.92

IRLAB Therapeutics AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

IRLAB Therapeutics AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	36.731	+	(24.626	+	-3.5527136788005E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	61.36

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	177.121	-	115.764
	=	61.36

IRLAB Therapeutics AB's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	34.381	+	(25.54	+	0.00099999999999767
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	59.92

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	136.667	-	76.745
	=	59.92

IRLAB Therapeutics AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

6IRA:Germany

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB (OSTO:IRLAB A) Headlines

No Headlines